These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 37018976)
1. New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling. Chen Y; Peng D Int Immunopharmacol; 2023 May; 118():110072. PubMed ID: 37018976 [TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Liu B; Wang Y; Zhang Y; Yan B Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521 [TBL] [Abstract][Full Text] [Related]
4. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751 [TBL] [Abstract][Full Text] [Related]
5. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related]
8. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. Lan NSR; Fegan PG; Yeap BB; Dwivedi G ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090 [TBL] [Abstract][Full Text] [Related]
10. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613 [TBL] [Abstract][Full Text] [Related]
11. A review of cardiovascular benefits of SGLT2 inhibitors. Zhang Y; Han Q Medicine (Baltimore); 2022 Sep; 101(36):e30310. PubMed ID: 36086785 [TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Verma S; McMurray JJV Diabetologia; 2018 Oct; 61(10):2108-2117. PubMed ID: 30132036 [TBL] [Abstract][Full Text] [Related]
13. SGLT2 Inhibitors and Their Antiarrhythmic Properties. Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Effect of SGLT2 Inhibitors. Pawlos A; Broncel M; Woźniak E; Gorzelak-Pabiś P Molecules; 2021 Nov; 26(23):. PubMed ID: 34885795 [TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Wojcik C; Warden BA Curr Cardiol Rep; 2019 Sep; 21(10):130. PubMed ID: 31522263 [TBL] [Abstract][Full Text] [Related]
17. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349 [TBL] [Abstract][Full Text] [Related]
18. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500 [TBL] [Abstract][Full Text] [Related]
19. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. Packer M; Anker SD; Butler J; Filippatos G; Zannad F JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320 [TBL] [Abstract][Full Text] [Related]
20. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Garcia-Ropero A; Santos-Gallego CG; Zafar MU; Badimon JJ Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):275-285. PubMed ID: 30822172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]